摘要
目的 :评价奥利司他治疗肥胖症患者的临床疗效。方法 :6 5例 30～ 6 0岁 ,体重指数 (BMI)≥ 2 8kg/m2 <4 2kg/m2 的肥胖患者在给予低热卡饮食的基础上被分为奥利司他治疗组和对照组。疗程 2 4周。结果 :奥利司他治疗组体重下降 7.4 2±3.38kg ,较对照组的体重下降 4 .2 5± 1.6 2kg有极显著差异 (P =0 .0 0 1) ;与对照组相比 ,奥利司他还能显著降低肥胖患者的腰围、收缩压及舒张压、血总胆固醇水平及低密度脂蛋白胆固醇水平 (P <0 .0 5 ) ;奥利司他显著降低肥胖合并高血糖患者的空腹血糖、餐后 2h血糖 (P =0 .0 0 1和P <0 .0 5 ) ,空腹血清胰岛素水平有一定程度的下降。奥利司他治疗组胃肠道反应大多为轻度 ,可自行缓解。结论 :奥利司他结合饮食治疗可得到更为显著的体重改善 ,同时有助于肥胖相关危险因素的改善。
Objective: To evaluate the clinical efficacy of orlistat in obese patients. Methods: 65 patients (age 30～60 years, body mass index 28～42kg/m 2) were divided into orlistat group and control group based on a controlled-energy diet for 24 weeks. Results: Orlistat-treated patients lost more weight 7.42±3.38kg than patients of control group did 4.25±1.62kg (P=0.001). The values of waist circumference, systolic blood pressure and diastolic blood pressure, serum levels of total cholesterol and low density lipoprotein-cholesterol of orlistat group were reduced significantly in comparison with control group (P<0.05). Treatment with orlistat was associated with improvements in fasting plasma glucose, postprandial glucose and insulin levels. The gastrointestinal adverse effects were mostly happened in orlistat-treated patients but mild and transient. Conclusion:Orlistat plus diet significantly promotes weight loss and improves some obesity-related disease risk factors.
出处
《中国临床医学》
2004年第3期335-337,共3页
Chinese Journal of Clinical Medicine
